| human | Q5 |
| P8446 | Gateway to Research person ID | ECFB970D-7876-4450-B318-B441DA11958D |
| P496 | ORCID iD | 0000-0003-1196-4414 |
| P6023 | ResearchGate contributions ID | 38345527 |
| P166 | award received | Member of the Academy of Science of South Africa | Q75746002 |
| P108 | employer | University of Cape Town | Q951305 |
| P734 | family name | Meintjes | Q32856266 |
| Meintjes | Q32856266 | ||
| Meintjes | Q32856266 | ||
| P735 | given name | Graeme | Q18342976 |
| Graeme | Q18342976 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q47549837 | A Diffuse Fine Papular and Pustular Rash in a Man With Advanced Human Immunodeficiency Virus and Diabetes |
| Q36871924 | A Glucuronoxylomannan-Associated Immune Signature, Characterized by Monocyte Deactivation and an Increased Interleukin 10 Level, Is a Predictor of Death in Cryptococcal Meningitis |
| Q30844823 | A Population Genomics Approach to Assessing the Genetic Basis of Within-Host Microevolution Underlying Recurrent Cryptococcal Meningitis Infection. |
| Q30672930 | A dimorphic fungus causing disseminated infection in South Africa. |
| Q38188277 | A neglected epidemic: fungal infections in HIV/AIDS. |
| Q46256434 | AIDS-Related Endemic Mycoses in Western Cape, South Africa, and Clinical Mimics: A Cross-Sectional Study of Adults With Advanced HIV and Recent-Onset, Widespread Skin Lesions. |
| Q38689620 | AIDS-Related Mycoses: Current Progress in the Field and Future Priorities. |
| Q34030928 | AIDS-related mycoses: the way forward |
| Q35776693 | AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial |
| Q46222855 | Access to flucytosine for HIV-infected patients with cryptococcal meningitis – an urgent need |
| Q38849472 | Acute Kidney Injury and Urinary Biomarkers in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis |
| Q36806209 | Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial |
| Q52641448 | Adult antiretroviral therapy guidelines 2017. |
| Q33540873 | Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases |
| Q59112474 | Aggressive worsening of Sézary syndrome during early antiretroviral therapy |
| Q28484347 | Altered ratio of IFN-γ/IL-10 in patients with drug resistant Mycobacterium tuberculosis and HIV- Tuberculosis Immune Reconstitution Inflammatory Syndrome |
| Q39129300 | Anaemia in patients with HIV-associated TB: relative contributions of anaemia of chronic disease and iron deficiency. |
| Q36409322 | Anemia, Blood Transfusion Requirements and Mortality Risk in Human Immunodeficiency Virus-Infected Adults Requiring Acute Medical Admission to Hospital in South Africa |
| Q46669303 | Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis |
| Q33783987 | Antiretroviral treatment outcomes amongst older adults in a large multicentre cohort in South Africa |
| Q37364438 | Assessing the contribution of the immune reconstitution inflammatory syndrome to mortality in developing country antiretroviral therapy programs |
| Q34311748 | Assessment at antiretroviral clinics during TB treatment reduces loss to follow-up among HIV-infected patients. |
| Q33903941 | Barriers to initiation of antiretrovirals during antituberculosis therapy in Africa. |
| Q47094578 | Benefits and risks of rapid initiation of antiretroviral therapy |
| Q40337163 | Brief Report: Flow Rate of Cerebrospinal Fluid Through a Spinal Needle Can Accurately Predict Intracranial Pressure in Cryptococcal Meningitis |
| Q98650971 | Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy |
| Q38596060 | Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis |
| Q34799534 | Central nervous system disorders after starting antiretroviral therapy in South Africa |
| Q37442512 | Central nervous system immune reconstitution inflammatory syndrome. |
| Q36407524 | Cerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for Cryptococcal Meningitis |
| Q35324835 | Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis |
| Q44170980 | Changing epidemiology of HIV-associated cryptococcosis in sub-Saharan Africa |
| Q28474814 | Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses |
| Q33547682 | Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors |
| Q57827529 | Clinical management of tuberculosis and HIV-1 co-infection |
| Q46168249 | Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected Africans |
| Q91650621 | Clinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: A prospective cohort study |
| Q36997522 | Combined therapy for tuberculosis and HIV-1: the challenge for drug discovery |
| Q46248271 | Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis |
| Q36877237 | Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome |
| Q28486096 | Complications of antiretroviral therapy initiation in hospitalised patients with HIV-associated tuberculosis |
| Q33621748 | Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis |
| Q38557982 | Conceptions of agency and constraint for HIV-positive patients and healthcare workers to support long-term engagement with antiretroviral therapy care in Khayelitsha, South Africa |
| Q43520823 | Contemporary disengagement from antiretroviral therapy in Khayelitsha, South Africa: A cohort study. |
| Q101575048 | Correlation between Blood and CSF Compartment Cytokines and Chemokines in Subjects with Cryptococcal Meningitis |
| Q36218302 | Corticosteroid therapy, vitamin D status, and inflammatory cytokine profile in the HIV-tuberculosis immune reconstitution inflammatory syndrome |
| Q36238260 | Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome |
| Q28534733 | Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa |
| Q36543833 | Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study |
| Q38046791 | Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation |
| Q34516548 | Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions |
| Q59115056 | Cryptococcal immune reconstitution inflammatory syndrome presenting with erosive bone lesions, arthritis and subcutaneous abscesses |
| Q59115042 | Cryptococcal meningitis--a neglected killer |
| Q36653764 | Cryptococcal meningoencephalitis relapse after an eight-year delay: an interplay of infection and immune reconstitution |
| Q35056457 | Cytotoxic mediators in paradoxical HIV-tuberculosis immune reconstitution inflammatory syndrome |
| Q36608014 | Dermatologic manifestations of the immune reconstitution inflammatory syndrome |
| Q35072106 | Detection of High Cerebrospinal Fluid Levels of (1→3)-β-d-Glucan in Cryptococcal Meningitis |
| Q37579943 | Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes |
| Q94479704 | Diagnostic accuracy of a novel tuberculosis point-of-care urine lipoarabinomannan assay for people living with HIV: A meta-analysis of individual in- and outpatient data |
| Q36315432 | Diagnostic accuracy, incremental yield and prognostic value of Determine TB-LAM for routine diagnostic testing for tuberculosis in HIV-infected patients requiring acute hospital admission in South Africa: a prospective cohort |
| Q38850833 | Differences in Immunologic Factors Among Patients Presenting with Altered Mental Status During Cryptococcal Meningitis |
| Q34251506 | Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis |
| Q40061579 | Disseminated tuberculosis among hospitalised HIV patients in South Africa: a common condition that can be rapidly diagnosed using urine-based assays |
| Q42219666 | Dosing of raltegravir when given with rifampicin |
| Q34255402 | Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases |
| Q35923885 | Early ART After Cryptococcal Meningitis Is Associated With Cerebrospinal Fluid Pleocytosis and Macrophage Activation in a Multisite Randomized Trial |
| Q33518021 | Early severe morbidity and resource utilization in South African adults on antiretroviral therapy |
| Q39777998 | Effect of HIV-1 infection on T-Cell-based and skin test detection of tuberculosis infection |
| Q39594106 | Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens |
| Q35946908 | Enhanced ex vivo stimulation of Mycobacterium tuberculosis-specific T cells in human immunodeficiency virus-infected persons via antigen delivery by the Bordetella pertussis adenylate cyclase vector |
| Q35353193 | Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis |
| Q34374785 | Failure to eradicate Isospora belli diarrhoea despite immune reconstitution in adults with HIV--a case series. |
| Q90171109 | False rifampicin resistant results using Xpert MTB/RIF on urine samples in hospitalised HIV-infected patients |
| Q51641993 | False-positive Xpert(®) MTB/RIF assays and previous treatment. |
| Q42211972 | False-positive Xpert® MTB/RIF assays in previously treated patients: need for caution in interpreting results. |
| Q38637694 | Flow Cytometry To Assess Cerebrospinal Fluid Fungal Burden in Cryptococcal Meningitis |
| Q112578499 | Flow cytometry method for absolute counting and single-cell phenotyping of mycobacteria |
| Q36517790 | Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome |
| Q59115058 | Fungal Burden, Early Fungicidal Activity, and Outcome in Cryptococcal Meningitis in Antiretroviral-Naive or Antiretroviral-Experienced Patients Treated with Amphotericin B or Fluconazole |
| Q35674504 | Genotypic Diversity Is Associated with Clinical Outcome and Phenotype in Cryptococcal Meningitis across Southern Africa |
| Q37287701 | HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients |
| Q36815449 | HIV-1 and the immune response to TB. |
| Q36654015 | HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome |
| Q37328357 | HIV-Related Medical Admissions to a South African District Hospital Remain Frequent Despite Effective Antiretroviral Therapy Scale-Up |
| Q36317866 | HIV-associated tuberculosis 2012. |
| Q36129630 | HIV-tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling |
| Q59115059 | Haemolytic anaemia associated with efavirenz |
| Q42091991 | Heart failure and cardiogenic shock associated with the TB-immune reconstitution inflammatory syndrome |
| Q33712746 | Hemostatic Changes Associated With Increased Mortality Rates in Hospitalized Patients With HIV-Associated Tuberculosis: A Prospective Cohort Study |
| Q33854516 | High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out |
| Q43678311 | High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial |
| Q36822539 | Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure |
| Q36488971 | Human Immune Response Varies by the Degree of Relative Cryptococcal Antigen Shedding |
| Q43037118 | Human immunodeficiency virus-associated tuberculosis. |
| Q35622163 | Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome |
| Q28476626 | Hypoxia induces an immunodominant target of tuberculosis specific T cells absent from common BCG vaccines |
| Q40761852 | Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa |
| Q46051910 | Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study |
| Q35100818 | Immune reconstitution inflammatory syndrome in HIV-infected patients |
| Q37058004 | Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy : pathogenesis, clinical manifestations and management |
| Q46245492 | Immune reconstitution inflammatory syndrome in a large multicenter cohort study: case definition and comparability |
| Q43966895 | Immunological characterisation of an unmasking TB-IRIS case. |
| Q36912524 | Implementation and Operational Research: Evaluation of a Public-Sector, Provider-Initiated Cryptococcal Antigen Screening and Treatment Program, Western Cape, South Africa |
| Q47328923 | Improved survival and antiretroviral treatment outcomes in adults receiving community-based adherence support: 5-year results from a multicentre cohort study in South Africa |
| Q41989084 | Incidence of Tuberculosis amongst HIV positive individuals initiating antiretroviral treatment at higher CD4 counts in the HPTN 071 (PopART) trial in South Africa |
| Q34247688 | Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients |
| Q33553788 | Inflammasome Activation Underlying Central Nervous System Deterioration in HIV-Associated Tuberculosis |
| Q35992186 | Interleukin 27R regulates CD4+ T cell phenotype and impacts protective immunity during Mycobacterium tuberculosis infection |
| Q36458503 | Interleukin-17 mediated differences in the pathogenesis of HIV-1-associated tuberculous and cryptococcal meningitis |
| Q59115033 | Large volume lumbar punctures in cryptococcal meningitis clear cryptococcal antigen as well as lowering pressure |
| Q46667507 | Linezolid for multidrug-resistant tuberculosis in HIV-infected and -uninfected patients |
| Q44771107 | Linezolid in drug-resistant tuberculosis: haste makes waste |
| Q38929509 | Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index |
| Q92758583 | Loss to follow-up from antiretroviral therapy clinics: A systematic review and meta-analysis of published studies in South Africa from 2011 to 2015 |
| Q41932850 | Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence |
| Q38850781 | Low incidence of the immune reconstitution inflammatory syndrome among HIV-infected patients starting antiretroviral therapy in Gabon: a prospective cohort study |
| Q41330886 | Lower-dose efavirenz: what is needed before implementation? |
| Q53798367 | Management challenges in tuberculosis and HIV. |
| Q34455442 | Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review |
| Q41664059 | Management of drug-resistant TB in patients with HIV co-infection |
| Q37666456 | Management of individuals requiring antiretroviral therapy and TB treatment |
| Q37546240 | Management of patients with the immune reconstitution inflammatory syndrome |
| Q38023242 | Management of the immune reconstitution inflammatory syndrome. |
| Q38107500 | Management of tuberculosis and latent tuberculosis infection in human immunodeficiency virus-infected persons |
| Q39569711 | Matrix Degradation in Human Immunodeficiency Virus Type 1-Associated Tuberculosis and Tuberculosis Immune Reconstitution Inflammatory Syndrome: A Prospective Observational Study |
| Q37712261 | Matrix metalloproteinases and tissue damage in HIV-tuberculosis immune reconstitution inflammatory syndrome |
| Q39101295 | Mortality in Severe Human Immunodeficiency Virus-Tuberculosis Associates With Innate Immune Activation and Dysfunction of Monocytes |
| Q24620256 | Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast |
| Q34282914 | Mycobacterial antigen driven activation of CD14++CD16- monocytes is a predictor of tuberculosis-associated immune reconstitution inflammatory syndrome |
| Q51869965 | Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. |
| Q46211844 | Neutrophil activation and enhanced release of granule products in HIV-TB immune reconstitution inflammatory syndrome |
| Q34488659 | Neutrophil-associated central nervous system inflammation in tuberculous meningitis immune reconstitution inflammatory syndrome |
| Q42394117 | Nosocomial drug-resistant bacteremia in 2 cohorts with cryptococcal meningitis, Africa |
| Q37331456 | Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance |
| Q33823233 | Optimum timing of antiretroviral therapy for HIV-infected patients with concurrent serious opportunistic infections |
| Q24678763 | Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole |
| Q33888707 | Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South Africa |
| Q38522810 | Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis |
| Q47644526 | Paradoxical respiratory failure due to cryptococcal pneumonia after amphotericin B treatment for HIV-associated cryptococcal meningitis. |
| Q35656939 | Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy |
| Q33337508 | Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: a cross-sectional study |
| Q59115007 | Phased implementation of screening for cryptococcal disease in South Africa |
| Q51367854 | Poor specificity of urinary cryptococcal antigen testing: Reply to Drain et al. Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu-Natal. |
| Q33916426 | Presentation and outcome of tuberculous meningitis in a high HIV prevalence setting. |
| Q37250893 | Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial). |
| Q37447797 | Prevention and treatment of the immune reconstitution inflammatory syndrome |
| Q37247445 | Procollagen III N-terminal propeptide and desmosine are released by matrix destruction in pulmonary tuberculosis |
| Q38854793 | Prognostic implications of baseline anaemia and changes in haemoglobin concentrations with amphotericin B therapy for cryptococcal meningitis |
| Q46819148 | Prolonged deferral of antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase mortality? |
| Q36146226 | Prolonged tuberculosis-associated immune reconstitution inflammatory syndrome: characteristics and risk factors |
| Q46852290 | Pulmonary cryptococcosis misdiagnosed as smear-negative pulmonary tuberculosis with fatal consequences |
| Q37846487 | Pulmonary manifestations of the immune reconstitution inflammatory syndrome |
| Q36223092 | Raised Venous Lactate and Markers of Intestinal Translocation Are Associated With Mortality Among In-Patients With HIV-Associated TB in Rural South Africa |
| Q34130659 | Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome |
| Q35036181 | Rapid diagnosis of cryptococcal meningitis by use of lateral flow assay on cerebrospinal fluid samples: influence of the high-dose "hook" effect |
| Q35746807 | Rapid microbiological screening for tuberculosis in HIV-positive patients on the first day of acute hospital admission by systematic testing of urine samples using Xpert MTB/RIF: a prospective cohort in South Africa |
| Q33968248 | Reduced referral and case fatality rates for severe symptomatic hyperlactataemia in a South African public sector antiretroviral programme: a retrospective observational study |
| Q37285167 | Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa |
| Q36365296 | Relationship Between Blood Concentrations of Hepcidin and Anemia Severity, Mycobacterial Burden, and Mortality Among Patients With HIV-Associated Tuberculosis |
| Q37365065 | Relationship Between HIV Coinfection, Interleukin 10 Production, and Mycobacterium tuberculosis in Human Lymph Node Granulomas. |
| Q46091639 | Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures |
| Q46909423 | Resistance matters in EARNEST. |
| Q26781111 | Risk Factors for Acquired Rifamycin and Isoniazid Resistance: A Systematic Review and Meta-Analysis |
| Q43287158 | Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study |
| Q36641645 | Role of the interleukin 10 family of cytokines in patients with immune reconstitution inflammatory syndrome associated with HIV infection and tuberculosis |
| Q90578032 | Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update |
| Q100992563 | Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update |
| Q35881241 | Sponsorship in non-commercial clinical trials: definitions, challenges and the role of Good Clinical Practices guidelines |
| Q36273077 | Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies |
| Q50659916 | Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. |
| Q28073480 | TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis |
| Q33732480 | TB-IRIS: Proteomic analysis of in vitro PBMC responses to Mycobacterium tuberculosis and response modulation by dexamethasone |
| Q35054462 | THE RISKS OF CONCURRENT TREATMENT WITH TENOFOVIR AND AMINOGLYCOSIDES IN PATIENTS WITH HIV-ASSOCIATED TUBERCULOSIS. |
| Q36471917 | Temporal trends in death causes in adults attending an urban HIV clinic in Uganda: a retrospective chart review |
| Q33858110 | Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme |
| Q33793447 | The CSF Immune Response in HIV-1-Associated Cryptococcal Meningitis: Macrophage Activation, Correlates of Disease Severity, and Effect of Antiretroviral Therapy |
| Q38515392 | The diagnosis, management and prevention of HIV-associated tuberculosis |
| Q35635476 | The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis |
| Q38774066 | The evolving role of CD4 cell counts in HIV care |
| Q38281773 | The future role of CD4 cell count for monitoring antiretroviral therapy |
| Q38127598 | The immunopathogenesis of the HIV tuberculosis immune reconstitution inflammatory syndrome |
| Q36846260 | The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis |
| Q44579727 | The value of blood culture audits at peripheral hospitals. |
| Q36337077 | Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study |
| Q35837236 | Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success |
| Q34024416 | Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis |
| Q36290487 | Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis |
| Q39297351 | Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. |
| Q37635400 | Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy |
| Q28749315 | Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings |
| Q37098501 | Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome |
| Q35801370 | Underestimation of the True Specificity of the Urine Lipoarabinomannan Point-of-Care Diagnostic Assay for HIV-Associated Tuberculosis |
| Q53836938 | Underestimation of the incremental diagnostic yield of HIV-associated tuberculosis in studies of the Determine TB-LAM Ag urine assay. |
| Q57827565 | Undiagnosed Active Tuberculosis in HIV‐Infected Patients Commencing Antiretroviral Therapy |
| Q41987250 | Urinary lipoarabinomannan detection and disseminated nontuberculous mycobacterial disease |
| Q33603890 | Utility of Second-Generation Line Probe Assay (Hain MTBDRplus) Directly on 2-Month Sputum Specimens for Monitoring Tuberculosis Treatment Response |
| Q42689781 | Ventriculoperitoneal shunt insertion for hydrocephalus in human immunodeficiency virus-infected adults: a systematic review and meta-analysis protocol. |
| Q33953918 | Very low levels of 25-hydroxyvitamin D are not associated with immunologic changes or clinical outcome in South African patients with HIV-associated cryptococcal meningitis |
| Q36422981 | Warfarin-induced skin necrosis in HIV-1-infected patients with tuberculosis and venous thrombosis. |
Search more.